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Abstract
Both hepatitis B virus (HBV) and aflatoxin B1 (AFB1) exposure can cause liver damage as well as increase the
probability of hepatocellular carcinoma (HCC). To investigate the underlying genetic changes that may influence
development of HCC associated with HBV infection and AFB1 exposure, HCC patients were subdivided into 4
groups depending upon HBV and AFB1 exposure status: (HBV(+)/AFB1(+), HBV(+)/AFB1(-), HBV(-)/AFB1(+),
HBV(-)/AFB1(-)). Genetic abnormalities and protein expression profiles were analyzed by array-based comparative
genomic hybridization and isobaric tagging for quantitation. A total of 573 chromosomal aberrations (CNAs) including
184 increased and 389 decreased were detected in our study population. Twenty-five recurrently altered regions
(RARs; chromosomal alterations observed in ≥10 patients) in chromosomes were identified. Loss of 4q13.3-q35.2,
13q12.1-q21.2 and gain of 7q11.2-q35 were observed with a higher frequency in the HBV(+)/AFB1(+), HBV(+)/
AFB1(-) and HBV(-)/AFB1(+) groups compared to the HBV(-)/AFB(-) group. Loss of 8p12-p23.2 was associated with
high TNM stage tumors (P = 0.038) and was an unfavorable prognostic factor for tumor-free survival (P =0.045). A
total of 133 differentially expressed proteins were identified in iTRAQ proteomics analysis, 69 (51.8%) of which
mapped within identified RARs. The most common biological processes affected by HBV and AFB1 status in HCC
tumorigenesis were detoxification and drug metabolism pathways, antigen processing and anti-apoptosis pathways.
Expression of AKR1B10 was increased significantly in the HBV(+)/AFB1(+) and HBV(-)/AFB1(+) groups. A significant
correlation between the expression of AKR1B10 mRNA and protein levels as well as AKR1B10 copy number was
observered, which suggest that AKR1B10 may play a role in AFB1-related hepatocarcinogenesis. In summary, a
number of genetic and gene expression alterations were found to be associated with HBV and AFB1- related HCC.
The possible synergistic effects of HBV and AFB1 in hepatocarcinogenesis warrant further investigations.
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Background
Hepatocellular carcinoma (HCC) is one of the most prevalent
human cancers worldwide [1]. Epidemiological evidence
suggests that several environmental factors are involved in the
development of HCC [2,3]. In Japan and the United States,
more than 70% of cases are related to chronic HCV infection
[4,5], while in Southern China and sub-Saharan Africa, HCC is
associated with high dietary exposure to aflatoxin B1 (AFB1)
and hepatitis B virus (HBV) infection and is the major causes of
cancer mortality in these geographic areas [3–5].
Hepatocarcinogenesis is a complex process associated with
the accumulation of genetic abnormalities that occur during
initiation, promotion, and progression of the disease [6]. Both
HBV infection and AFB1 exposure can cause liver damage,
and increase the probability of HCC [2,7]. They appear to play
different roles in HCC development due to their various
biological effects. AFB1 is the most prevalent and carcinogenic
of the aflatoxins. When ingested, AFB1 is processed in the liver
by the cytochromes P450 system to reactive epoxides which
can damage DNA [8,9]. A number of studies have confirmed
that more than 50% of HCC patients who have been exposed
to AFB1 carry a mutation in codon 249 (AGGArg→AGTSer or
AGGArg→AGCSer) of the p53 gene [9–11]. This hotspot mutation
is considered a molecular marker reflecting AFB1-induced DNA
damage that eventually results in HCC [12–14].
Previous microarray chromosomal proteomic studies have
identified genes or chromosomal regions that may be involved
in hepatocarcinogenesis [15–20]. These findings indicate that
development of HCC is a complex polygene and multi-pathway
process [21]. Genetic pathways associated with development
of HBV-related HCC include RB1, methylation of p16INK4a,
and amplification of Cyclin D1 [21]. In contrast, AFB1 alters the
protein sequence of the tumor suppressor p53 gene which
regulates the cell cycle and is important in conserving genome
stability. Other ways by which AFB1 may act to promote HCC
are poorly understood. HBV and AFB1 are also thought to
influence the activity of similar pathways to promote HCC.
Currently, it is not clear if these two pathways can act
synergistically to promote HCC via common or overlapping
molecular mechanisms. It is important to understand how HBV
and AFB1 affect HCC development in China where there is
high exposure to both HBV and AFB1.
In this study, we used array-based comparative genomic
hybridization (aCGH) and Isobaric Tagging Reagent
Quantitative (iTRAQ) proteomics to identify chromosomal
regions and proteins/genes that are altered as a result of HBV
and AFB1 exposure. The results of this study may provide
additional markers and molecular targets for the diagnosis and
treatment of these types of HCC.
Methods
This study enrolled 157 patients with HCC from the Tumor
Hospital of Guangxi Medical University and First Affiliated
Hospital of Guangxi Medical University, Nanning, Guangxi
Province, China. 32 of which were enrolled for array-based
comparative genomic hybridization and isobaric tagging
reagent quantitative analysis. The study was approved by the
both hospitals’ institutional review boards and was performed
according to the Declaration of Helsinki. All patients gave their
informed consents.
Study patients
All patients (ages 23-75 years) had HCC and were negative
for HCV (as determined by serology and pathological
analyses). All study patients were subjected to a rigorous
screening procedure before they were categorized into
subgroups. We defined HBV- related and AFB1- related status
in this study by the following criteria: The HBV- related (HBV
(+)) patients were defined as HBsAg-positive, HBeAb-positive
(or HBeAg-positive) and anti-HBc-positive. These patients all
had > 1000 copies of serum HBV-DNA. In contrast, the HBV-
negative (HBV (-)) patients were negative for HBsAg, HBeAg
and anti-HBc. They also had undetectable serum HBV-DNA.
All HBV-negative (HBV (-)) patients were positive for HBsAb
protective antibodies. AFB1-related patients were classified on
the basis of a G to T transversion in codon 249 of the p53 gene
(AGGArg→AGTSer or AGGArg→AGCSer ) that results in a change
from Arg to Ser in the protein sequence. AFB1- related
(AFB1(+)) status was defined as the presence of the codon 249
mutations in p53 together with positive staining for AFB1-DNA
in HCC tissues (Figure S1). AFB1- negative (AFB1(-)) status
was defined as the absence of mutations in codon 249 of p53
as well as absence of AFB1-DNA in HCC tissue. Specimens
which were AFB1-DNA positive but the p53 codon 249
mutation negative or specimens which were the p53 codon 249
mutation positive but AFB1-DNA negative were excluded from
the study. For the iTRAQ quantitative proteomics analysis,
normal hepatic tissue from hepatic hemangioma, liver
resections and liver transplant donors were used as normal
controls.
Immunohistochemical staining for AFB1-DNA[22]
Although the mutation in codon 249 of the p53 gene is
associated with AFB1 intake, this mutation is not carcinogen-
specific and may also be seen in patients with HBV-related or
HCV-related HCC. Serum AFB1 albumin adducts have been
shown to help determine AFB1 intake. However, in this study,
we determined AFB1 intake using a modification of a
previously described method for AFB1 exposed tissue AFB1-
DNA adduct immunohistochemistry [22] .
Briefly, 4-mm-thick paraffin sections were dewaxed in xylene
and rehydrated using a descending alcohol gradient. The
sections were then washed in 0.5 M glycine in phosphate-
buffered saline (PBS; pH 7.2) to inhibit/remove fixing agents,
which can cause nonspecific binding of immunoperoxidase or
reduce 30, 30-diaminobenzidine tetrahydrochloride (DAB)
levels. Endogenous peroxidase activity was blocked by
incubating the sections in 0.3–0.5% H2O2 in absolute methanol
for 30 min. The slides were then washed in Tris buffer for 5 min
and incubated with a few drops of 3% normal goat serum for 30
min. The sections were incubated overnight at 4°C with a 1:100
dilution of anti-AFB1 antibody [monoclonal anti-aflatoxin B1
(6A10); Novus Biolocals Inc., Littleton, CO, USA]. After the
sections were washed three times with PBS, they were
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incubated with a biotin-conjugated secondary antibody (Sigma-
Aldrich; St. Louis, MO, USA) at 37°C with a 1:2000 dilution for
30-50 min, followed by peroxidase-conjugated streptavidin for
30 min. Peroxidase activity was detected by incubating the
sections in DAB for 10 min followed by counterstaining with
Mayer’s haematoxylin. The sections were then dehydrated in
alcohol, cleared in xylene and mounted with malinol. The
labeling index was used to evaluate sections immuno-stained
for AFB1. All evaluations were independently performed by two
pathologists (S.J. O’Brien and Z-N Mo) who were blinded to the
patients’ status. At least 1000 nuclei were counted at random in
noncancerous hepatocytes from at least two sections at a
magnification of ×400. Sections in which ≥ 5% of the hepatic
nuclei expressed AFB1 were considered to be AFB1 positive.
Array-based comparative genomic hybridization
(aCGH)
Genomic DNA from tumors and control lymphocytes was
digested with AluI and RsaI (Promega, Madison, WI, US) and
labeled with Cy5 and Cy3 respectively, using Agilent Genomic
DNA Labeling Kit PLUS (Agilent Technologies, Santa Clara,
CA, US) per manufacturers’ instructions. Labeled DNA
fragments were purified and specific activity determined.
Array hybridization was performed using Agilent Oligo aCGH
Hybridization Kit (Agilent Technologies) per manufacturer’s
instructions and arrays were scanned by Agilent Microarray
Scanner (Agilent Technologies). The Z-score for each
chromosomal aberrations region was calculated using DNA
Analytics 6.5.0.58 software (Agilent Technologies)
DNA purification and analysis of exon 7 of p53
mutation
Tumor tissues and normal lymphocytes (control) were
collected during liver resection and frozen at -80°C. All sample
had > 70% viable tumor cells as determined by pathological
examination. Genomic DNA was extracted from tumor samples
and lymphocytes using the Dneasy Tissue kit (Qiagen, Hilden
Germany) according to the manufacturer’s instructions. Exon 7
of p53 was amplified using the forward and reverse primers 5’-
cttgccacaggtctccccaa-3’ and 5’-aggggtcagcggcaagcaga-3’
(237bp), respectively, under standard cycling conditions.
Purified PCR products were sequenced to evaluate the
presence of the AGGArg→AGTSer or AGGArg→AGCSer mutation
at codon 249.
iTRAQ labeling and 2DLC_ESI_MS/MS
HCC and normal hepatic tissue (0.2 g each) were ground
into powder in liquid nitrogen with a precooled mortar and
pestle. Samples were then homogenized on ice in 1 ml of lysis
buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-Cl, pH
8.5, protease inhibitor mixture) using a glass homogenizer.
After sonication on ice for 10 seconds using an ultrasonic
processor, the samples were centrifuged for 30 min at 12,000
rpm to remove particulate materials. Protein concentrations
were determined in duplicate by the Bradford method (Bio-Rad)
and confirmed by SDS-PAGE.
The extracted proteins from samples within each group (i.e.,
HBV(+)/AB1(+) HBV(+)/AFB1(-), HBV(-)/AFB1(+), and HBV(-)/
AFB1(-) were precipitated with isopropanol, and pellets were
redissolved in the dissolution buffer (0.5M triethylammonium
bicarbonate, 0.1% SDS). The subsequent protein samples
were quantified and 100 µg of protein was denatured,
alkylated, and digested.
Proteins were labeled with the iTRAQ tags as follows: normal
liver tissues: 113 isobaric tag, HBV(+)/AFB1(+) group: 116
isobaric tag, HBV(+)/AFB1(-) group: 117 isobaric tag, HBV(-)/
AFB1(+) group: 118 isobaric tag, HBV(-)/AFB1(-) group:119
isobaric tag. The labeled samples were combined, desalted
with Sep-Pak Vac C18 cartridge 1 cm3/50mg (Waters, Milford
Massachusetts USA), and fractionated by using a Shimazu
UFLC system (Shimadzu Corp, Kyoto Japan) connected to a
strong cation exchange (SCX) column (polysulfethyl column,
2.1mm-100 mm, 5 uL, 200 Å, (The Nest Group Inc.,
Southborough, MA USA).
SCX separation was performed using a linear binary gradient
of 0-45% buffer B (350mM KCl, 10mM KH2PO4 in 25% ACN,
pH 2.6) in buffer A (10mM KH2PO4 in 25% ACN, pH2.6) at a
flow rate of 200 uL/min for 90 min, and 30 fractions were
collected every 3 min. Each fraction was dried down and
redissolved in buffer C (5% (v/v) acetonitrile and 0.1% formic
acid solution), and the fractions with high KCl concentration
were desalted with PepClean C-18 spin columns (Pierce,
Waltham USA). All SCX fractions were analyzed 3 times using
a QSTAR XL LC/MS/MS system (Applied Biosystems, Foster
City, California USA) and RPLC column (ZORBAX 300SB-C18
column, 5 μm, 300 Å, 0.1 mm -15 mm [Microm, Auburn, CA
US]). The RPLC gradient was 5% to 35% buffer D (95%
acetonitrile, 0.1% formic acid) in buffer C at a flow rate of 0.3
uL/min in 120 min.
The Q-TOF instrument was operated in positive ion mode
with ion spray voltage typically maintained at 2.0 kV. Mass
spectra of iTRAQ labeled samples were acquired in an
information-dependent acquisition mode. The analytical cycle
consisted of a MS survey scan (400-2000 m/z) followed by 5-s
MS/MS scans (50-2000) of the 5 most abundant peaks (i.e.,
precursor ions), which were selected from the MS survey scan.
Precursor ion selection was based upon ion intensity (peptide
signal intensity above 25 counts/s) and charge state (2+ to 4+).
Once the ions were fragmented in the MS/MS scan, they were
allowed one repetition before a dynamic exclusion for a period
of 120 sec. Because of the iTRAQ tags, the parameters for
rolling collision energy were manually optimized. Under CID,
iTRAQ-labeled peptides fragmented to produce reporter ions at
113.1, 116.1, 117.1, 118.1 and 119.1, and fragment ions of the
peptides were simultaneously produced, resulting in
sequencing of the labeled peptides and identification of the
corresponding proteins. The ratios of the peak areas of the
three iTRAQ reporter ions reflected the relative abundances of
the peptides and the proteins in the samples. Calibration of the
mass spectrometer was carried out using BSA tryptic peptides.
Database Searching and Criteria
Protein identification and quantification for the iTRAQ
experiment was performed with the ProteinPilot software
version 3.0 (Applied Biosystems). The Paragon Algorithm in
HBV and AFB1 Related HCC Analysis in Guangxi
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e83465
ProteinPilot software was used for peptide identification and
isoform specific quantification.
To minimize false positive results, a strict cutoff for protein
identification was applied with the unused ProtScore g1.3,
which corresponds to a confidence limit of 95%, and at least
one peptide with the 95% confidence was considered for
protein quantification. The resulting data set was auto bias
corrected to remove any variations due to unequal mixing
during the combining of different labeled samples. For iTRAQ
quantitation, the peptide for quantification was automatically
selected by the Pro Group algorithm (at least one peptide with
99% confidence) to calculate the reporter peak area, error
factor (EF), and P-value.
AKR1B10 mRNA and Western blot analysis
To validate differential expression indicated by the aCGH
and proteomic analysis (see above), the levels of RNA and
protein of 157 samples from this study were analyzed by RT-
PCR and Western blot.
Total RNA was extracted with RNAsimple Total RNA Kit
(Tiangen Biotech, Beijing, China) and purified with the RNeasy
Mini kit (Qiagen) according to the manufacturers’ instructions.
cDNA was synthesized with the RevertAid™ First Strand cDNA
Synthesis Kit (Thermo Scientific ) according to the
manufacturer’s instructions. AKR1B10 cDNA was amplified
using the forward and reverse primers 5'-
cccaaagatgataaaggtaatgccatcggt-3’ and 5'-
cgatctggaagtggctgaaattggaga-3’, respectively. GAPDH cDNA
was amplified as a control using the forward and reverse
primers 5’-atgaccccttcattgacc-3’ and 5’-
gaagatggtgatgggatttc-3’, respectively. All cDNA amplification
was peformed using standard conditions.
For Western analysis, pooled samples used in the iTRAQ
experiment that contained 20μg of total proteins were
separated by 10% (w/v) SDS-PAGE and transferred onto a
PVDF membrane (Millipore, USA). Blots were incubated with
anti-AKR1B10 antibodies (1:1500 dilution; Abcam, Cambridge,
MA, USA) and subsequently incubated with anti-mouse or anti-
rabbit horseradish peroxidase-conjugated antibody. Proteins
were visualized with ECL Western blotting detection reagents
(Pierce Thermo Scientific) and bands quantified using
QUANTITY ONE software (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Continuous variables were presented as median and inter-
quartile range due to the small sample size. AKR1B10 mRNA
and protein expression level in the four HBV/AFB1 exposure
groups were compared by one-way ANOVA with LSD post-hoc
tests. The association of 25 recurrently altered regions (RARs)
with histological grade, TNM stage, and HBV/AFB1 exposure
groups were assessed by Fisher’s exact test, and Benjamini
and Hochberg procedure was used for control false discovery
rate (FDR). Cox proportional hazard models were performed to
determine independent influence factors of tumor-free survival.
Variables statistically significant in univariable analyses were
stepwise entered into the multivariable analysis. Statistical
analyses were two-sided and P-value < 0.05 was considered
statistically significant. Statistical analyses were performed
using SPSS 15.0 software (SPSS, Chicago, IL).
Results
Baseline demographics and disease characteristics of
32 patients for aCGH and iTRAQ analysis
All 32 patients were categorized into 4 groups depending
upon their HBV and AFB1 status. The categories were:
HBV(+)/AFB1(+) group (n = 10); HBV(+)/AFB1(-) group (n =
10); HBV(-)/AFB1(+) (n = 6); and HBV(-)/AFB1(-) (n = 6). The
average age of the study population was about 50 years, most
were male (93.8%), most had liver cirrhosis (87.5%), and about
half were HBV and AFB1 positive. About 53.1% of patients had
Edmondson grade of II and 56.3% of patients had TNM stage
of I+II. There was no significant difference in clinical
characteristics between groups. (Table S1). A total of 23
patients had a long history of smoking. Of these patients, 7
were in the HBV (+) / AFB1 (+) group, 8 were in the HBV (+) /
AFB1 (-) group, 5 were in the HBV (-) / AFB1 (+) group and 6
were in the HBV (+) / AFB1 (+) group. None of the patients had
a family history of liver cancer or a history of drinking (all
patients were negative for long-term exposure to
alcohol).Tumor-free rate was defined as the percentage of
study subjects without recurrence of the tumor at given time
points after surgery. The six-month, 1-year, and 2-year tumor-
free rates were 56.2%, 35.8%, and 21.8%.
Chromosomal alterations in patients with HCC
Analysis of chromosomal alterations indicated that
chromosomal abnormalities were observed in the tumors of the
HCC patients (Figure 1). Chromosomal instability was not
equally distributed across all the chromosomes. Of a total of
573 chromosomal aberrations, 184 resulted in increased
(gains) and 389 in decreased (losses) genetic material. The
mean gains or losses of genetic material per patient were 5.7
and 12.2, respectively. Genetic alterations across
chromosomal arms were detected in at least 7 tumors (21.9%)
including increased chromosomal DNA in 1q, 4p, 5p, 6p,7p, 8q,
10p, 17q, 20p, 20q and X and decreased chromosomal DNA in
1p, 2q, 4q, 8p, 9p, 10q, 11q, 13q, 14q, 16p, 16q ,17p ,19p ,19q,
21q, 22q ,Y (Figure 1).
Recurrently altered regions (RARs) in HCC tumors
To identify genetic regions that were sensitive to genetic
alterations, we defined the recurrently altered regions (RARs)
as regional chromosomal alterations observed in tumors from
≥10 patients. We detected a total of 25 RARs (including 8
RARs that increased and 17 RARs that decreased in copy
number) (Table 1). These regions contain a number of
oncogenes (e.g., MYC, FGF, EGFR and CCND3), tumor
suppressor genes (e.g., TP53, PTEN, RB1, BRCA2, CDKN2A
and CDKN2B), detoxification and drug metabolism genes (e.g.,
GSTA1, ADH4, ADH5, ADH6, ADH7, ADH1A, ADH1B,
ADH1C, CYP27A1, EPHX1, EPHX2, AKR1B10, AKR7A2 and
AOX1) as well as genes involved in a number of other cellular
processes (Table 1).
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Figure 1.  Whole-genome profiles and frequency plots of chromosomal alterations in HCC patients (z-scoring:2.5).  (A) The
genomic alterations in tumor samples from each HCC patient (n = 32) are illustrated in individual vertical lanes. A total of 573 gene
copy number alterations were mapped and ordered by chromosomal position from 1pter to Yqter using the workbench Lite Edition
6.5.0.18. Tumor versus the reference intensity ratios (in log2 ratio) for individual tumor samples are plotted in different color scales
reflecting the extent of increases (red) or decreases (green) in copy number. The detail chromosomal alterations were shown in 1B
(chromosome 1 to chromosome 12) and in 1C (chromosome 13 to chromosome 22, X chromosome and Y chromosome,
respectively). Nine chromosomes showed increased chromosomal DNA (1q, 5p, 6p,7q, 8q, 17q, 20p, 20q and X) and 16
chromosomes had deceased chromosomal DNA (1p, 4q, 8p, 9p, 10q,13q, 14q, 16p, 16q ,17p ,18q, 19p ,19q, 21q, 22q and Y) that
were repeatedly observed in > 20% of tumor samples.
doi: 10.1371/journal.pone.0083465.g001
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Table 1. Recurrently altered regions (RARs) arranged by
chromosomal location (Z-score: 2.5|log2ratio|>0.225).
Chromosome
Position
Change in
chromosomal
DNA (Gain/
Loss)
Number
of cases
Previously Reported Cancer-
related Genes
1p31.2-p36.2 loss 16
AKR7A2, PRDM2, RIZ, RAD54L,
FAF1, STIL, CDKN2C, TTC4, JUN,
ARHI, PRDM2, RIZ, CASP9, PGM1,
ENO1
1q21.1-q44 gain 20
PDZK1, MCL1, ARNT, AF1Q, TPM3,
ADAR, RPS27, HAX1, PYGO2,
CKS1B, ADAM15, MUC1, HDGF,
CCT3, PRCC, IFI16, AIM2, USF1,
SELP, SELE, LAMC2, TPR, PTGS2,
KIF14, ELF3, MDM4, ATF3, TGFB2,
WNT3A, AKT3, EPHX1
2q23.2-q37.2 loss 11 AOX1, CYP27A1, HSPD1, HSPE1
4q13.3-q35.2 loss 22
ADH4, ADH5, ADH6, ADH7, ADH1A,
ADH1B, ADH1C, HADH, ACSL1,
FGA, FGB, ACSL1 , CASP3, FAT,
FSTL5, VEGFC,
5p13.2-p15.3 gain 11 AMACR
6p12.1-p25.2 gain 13
HIST1H2AA , HIST1H2AI,
HIST1H2AJ, HIST1H2AK,
HIST1H1B, HIST1H4A , HIST1H5A,
HIST1H2BJ , HIST1H2BJ ,
HSP90AB1, HSPA1A , HMGA1,
NOTCH4, MAPK14, PIM1, TFEB,
CCND3,VEGF, GSTA1, DEK, ID4,
E2F3, PRL,MICA, MICB,
6q14.1-q26 loss 10
CCNC, GRIK2, CRSP3,
PLAGL1,SASH1, LATS1, IGF2R,
UNC93A, MLLT4, GOT2
7q11.2-q35 gain 13
AKR1B10, HGF, DMTF1, ABCB1,
EPO, EPHB4, PIK3CG, PDIA4,
CAV1,CAV2, MET, WNT2,
MDH2,CALD1
8p12-p23.2 loss 19
EPHX2, CSMD1, DEFB1, NAT1,
NAT2, PSD3, TNFRSF10A,
TNFRSF10B, TNFRSF10C,
RHOBTB2,
8q11.2-q24.3 gain 22
PRKDC, MCM4, SNAI2, LYN, MOS,
PLAG1, COPS5, TPD52, E2F5,
MMP16, NBS1,EIF3S3, C-MYC,
KCNK9, PTK2, EIF2C2, CCNE2
9p21.1-p24.2 loss 12 SMARCA2, MTAP, CDKN2B,CDKN2A, RECK, PAX5
10q21.3-q26.2 loss 12 PTEN, CYP2E1, ECHS1
13q12.1-q21.2 loss 13
RB1, BRCA2, XPO4,CCNA1,
RFP2, DDX26, DLEU1
DLEU2
14q21.3-q32.2 loss 13 AKT1, PCK2,PYGL ,HSP90AA1
16p12.1-p13.2 loss 14 SULT1A1, SOCS1, ERCC4, GNMT ,ABAT
Two chromosomal regions showed an association of
instability with tumor stage. Loss of 8p12-p23.2 was
significantly higher in high stage tumors compared to low stage
tumors (TNM I-II: 38.9% vs. TNM III: 92.9%; P = 0.038) and
loss of 19p13.1-p13.3 was also significantly higher in high
stage tumors compared to low stage tumors (TNM I-II: 33.3%
vs. TNM III: 92.9%; P = 0.025) (Table S2). There was no
association of any RAR with Edmondson grade (all P-values >
0.05).
Association between RARs and HBV status and AFB1
exposure
We analyzed the association of the different groups (HBV(+)/
AFB1(+), HBV(+)/AFB1(-), HBV(-)/AFB1(+) and HBV(-)/
AFB1(-)) with occurrence of RARs and found that all 4 groups
showed a high incidence of chromosomal alterations (≥50%) at
RAR: 8q11.2-q24.3, 17p12-p13.3, 19p13.1-p13.3 (Table 2).
Loss of 4q13.3-q35.2, 13q12.1-q21.2, and gain of 7q11.2-q35
were observed with a higher frequency in the HBV(+)/AFB1(+),
HBV(+)/AFB1(-) and HBV(-)/AFB1(+) groups compared to the
HBV(-)/AFB(-) group (Figure 2). Despite the small numbers in
the 4 groups, we found no statistical difference among the 4
groups in the incidence of a particular RAR. When analyzing a
single factor by itself, a higher incidence of RARs was
observed in 4q13.3-q35.2 among HBV-positive patients
compared to HBV-negative patients (85.0% vs. 41.7%, P =
0.018). However, after using the Benjamini Hochberg analysis
to control for false positives, this was non-significant (Table
S3).
Univariate and multivariate analysis of patient
characteristics and RARs with tumor-free survival
Univariate analysis found an association of tumor-free
survival with tumor size, serum AFP ≥ 400 ng/mL, BCLC, TNM
Table 1 (continued).
Chromosome
Position
Change in
chromosomal
DNA (Gain/
Loss)
Number
of cases
Previously Reported Cancer-
related Genes
16q12.1-q24.1 loss 21
ARG1, CDH1,
CDH3,CDH13,BCAR1, WWOX,
WFDC1
17p12-p13.3 loss 25 TP53 , MYH10
17q12-q25.2 gain 10 HLF, MPO, PPM1D, BCAS3, TBX2
18q12.3-q22.3 gain 10 --
19p13.1-p13.3 loss 19
CD97,DDX39, PRKCL1, EIF3S4,
DNMT1, P2RY11
KIAA1198,
19q13.2-q13.4 loss 10 CCNE1, APOE
21q21.3-q22.2 loss 11 ADAMTS1, SOD1 , FTCD
22q11.2-q13.2 loss 10 COMT
X gain 11 --
Y loss 14 --
doi: 10.1371/journal.pone.0083465.t001
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stage, invasion and metastasis, and loss of 8p12-p23.2 and
19p13.1-p13.3 (all P-values ≤ 0.025) (Table 3). Multivariate
analysis showed that serum AFP (≥400), TNM stage, loss of
8p12-p23.2 were independent factors associated with tumor-
free survival (all P-values ≤ 0.045) (Table 3).
iTRAQ Analysis of differentially expressed proteins in
HCC tumors
Using mass spectrophotometry, we identified differentially
expressed proteins by the following criteria: unused protein
score was more than 1.3 (99% confidence) per experiment;
one or more peptide hits were found per protein at > 95%
Table 2. The comparison of incidence of RARs in 32 HCCs
by HBV and AFB1 status.
Chromosome Group
Adjusted
P-value#
 
HBV(+)/
AFB1(+)
HBV(+)/
AFB1(-)
HBV(-)/
AFB1(+)
HBV(-)/
AFB1(-)  
 (n=10) (n=10) (n=6) (n=6)  
1p31.2-p36.2 6 (60.0%) 5 (50.0%) 2 (33.3%) 3 (50.0%) 0.977
1q21.1-q44 6 (60.0%) 7 (70.0%) 2 (33.3%) 5 (83.3%) 1.000
2q23.2-q37.2 4 (40.0%) 2 (20.0%) 2 (33.3%) 3 (50.0%) 0.958
4q13.3-q35.2 10(100.0%) 7 (70.0%) 3 (50.0%) 2 (33.3%) 0.400
5p13.2-p15.3 2 (20.0%) 4 (40.0%) 1 (16.7%) 4 (66.7%) 1.000
6p12.1-p25.2 3 (30.0%) 3 (30.0%) 4 (66.7%) 3 (50.0%) 1.000
6q14.1-q26 2 (20.0%) 4 (40.0%) 1 (16.7%) 3 (50.0%) 1.000
7q11.2-q35 7 (70.0%) 3 (30.0%) 2 (33.3%) 1 (16.7%) 1.000
8p12-p23.2 8 (80.0%) 4 (40.0%) 3 (50.0%) 5 (83.3%) 1.000
8q11.2-q24.3▲ 7 (70.0%) 6 (60.0%) 6 (100.0%) 3 (50.0%) 1.000
9p21.1-p24.2 5 (50.0%) 3 (30.0%) 2 (33.3%) 2 (33.3%) 0.934
10q21.3-q26.2 5 (50.0%) 3 (30.0%) 3 (50.0%) 1 (16.7%) 0.953
13q12.1-q21.2 7 (70.0%) 4 (40.0%) 2 (33.3%) 0 (0.0%) 0.613
14q21.3-q32.2 5 (50.0%) 3 (30.0%) 2 (33.3%) 3 (50.0%) 0.996
16p12.1-p13.2 4 (40.0%) 5 (50.0%) 2 (33.3%) 3 (50.0%) 0.963
16q12.1-q24.1 7 (70.0%) 7 (70.0%) 2 (33.3%) 5 (83.3%) 1.000
17p12-p13.3▲ 10(100.0%) 7 (70.0%) 4 (66.7%) 4 (66.7%) 1.000
17q12-q25,2 5 (50.0%) 3 (30.0%) 1 (16.7%) 1 (16.7%) 1.000
18q12.3-q22.3 4 (40.0%) 2 (20.0%) 3 (50.0%) 1 (16.7%) 1.000
19p13.1-
p13.3▲ 7 (70.0%) 5 (50.0%) 4 (66.7%) 3 (50.0%) 0.996
19q13.2-q13.4 4 (40.0%) 4 (40.0%) 1 (16.7%) 1 (16.7%) 0.920
21q21.3-q22.2 2 (20.0%) 4 (40.0%) 3 (50.0%) 2 (33.3%) 0.958
22q11.2-q13.2 4 (40.0%) 1 (10.0%) 2 (33.3%) 3 (50.0%) 1.000
X 3 (30.0%) 2 (20.0%) 3 (50.0%) 3 (50.0%) 0.950
Y※ 4 (44.4%) 3 (33.3%) 4 (66.7%) 3 (50.0%) 0.926
# Benjamini and Hochberg procedure was used for control false discovery
rate (FDR).
▲ High incidence of chromosomal alterations (≥50%) in all four groups are
highlighted in bold.
※1 out of 10 patients is female in HBV(+)/AFB1(+) and HBV(+)/AFB1(-) groups,
respectively.
doi: 10.1371/journal.pone.0083465.t002
confidence per peptide, and the ratio of expression in HCC
tumors versus control liver tissue differed by at least 2-fold in
the total population or 0.5-fold in the four sub-groups. After
meeting these criteria the identified proteins (n = 649) were
subsequently filtered with manually selected filter exclusion
parameters.
We identified a total of 133 differentially expressed tumor
proteins (59 proteins were significantly up-regulated and 74
proteins were significantly down-regulated) relative to control
liver tissue in the four groups (122, 110, 120 and 84 proteins in
HBV(+)/AFB1(+), HBV(+)/AFB1(-), HBV(-)/AFB1(+) and
HBV(-)/AFB1(-) groups, respectively) (Figure 3 and Table S4).
Of these 133 proteins, 72 were commonly up-regulated or
down-regulated in all of the 4 subgroups, and 24 were
commonly changed in HBV(+)/AFB1(+), HBV(+)/AFB1(-), and
HBV(-)/AFB1(+) groups (Figure 3). We found that 69 (51.8%) of
the 133 differentially expressed proteins mapped within the 25
identified RARs, and a number of them (AKR1B10, AKR7A2,
ENO1, EPHX2, ADH1, ADH1C, ADH1A, ADH6, GSTA1,
APOE, HSP90AA1, GNMT, COMT, HIST1H2AA, HIST1H1B ,
ARG1, ect ) are cancer-related genes (Table 1 and Table S3).
Using DAVID (http://david.abcc.ncifcrf.gov) to classify the
molecular processes that may be affected by the altered
protein expression, we showed that 62 of the 133 differentially
expressed proteins were involved in 13 biological pathways.
These included detoxification and drug metabolism; antigen
processing and presentation; glycolysis; anti-apoptosis;
response to unfolded protein; macromolecular complex
assembly; steroid metabolic process; coenzyme metabolic
process; homeostasis in body; fatty acid metabolic process;
response to nutrient levels; circulatory system process and
cytoskeleton organization (Table 4).
AKR1B10 mRNA and protein analysis
One protein that was differentially expressed among the 4
patient groups was aldo-keto reductase family 1 member B10
(AKR1B10); AKR1B10 protein levels were high in HBV(+)/
AFB1(+) and HBV(-)/AFB1(+) groups (9.22 and 5.15,
respectively) and lower in HBV(+)/AFB1(-) and HBV(-)/AFB1(-)
groups (2.00 and 1.10, respectively). AKR1B10 is located on
RAR: 7q11.2-q35 (position 7q33.1), a chromosomal region that
showed a high instance of instability (Figure 4A).
The AKR1B10 mRNA and protein expression levels in 32
HCC tumor samples and correlations among the expression of
AKR1B10 mRNA, protein levels and AKR1B10 copy number
were investigated first. The regression analysis showed a
significant correlation between the expression of AKR1B10
mRNA and protein levels and AKR1B10 copy number (Figure
4B, 4C). A total of 157 samples comprising (HBV(+)/AFB1(+)
(n=52), HBV(+)/AFB1(-) (n=50), HBV(-)/AFB1(+) (n=30) and
HBV(-)/AFB1(-) (n=25)) were subjected to RT-PCR and
Western blot analysis in order to further analyze the
association between AKR1B10 expression and HBV status and
AFB1 exposure.
The mean expression level of AKR1B10 mRNA was
significantly higher in the HBV(+)/AFB1(+) group compared to
the other three groups (1.88 vs. 1.11, 1.53, and 0.76, P ≤
0.008). Samples from the HBV(-)/AFB1(+) group also showed
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significantly higher AKR1B10 mRNA levels compared to the
HBV(-)/AFB1(-) group (1.53 vs. 0.76, P<0.001) and the
HBV(+)/AFB1(-) group (1.53 vs. 1.11, P = 0.001). In addition,
the HBV(+)/AFB1(-) group also showed significantly higher
Figure 2.  Representative comparison of incidence of RAR:4q12-q35.2、RAR:13q12.1-q21.1 and RAR:7q11.2-q35 in the 4
groups based on HBV and AFB1 status.  (%). Red bar: the loss of chromosome; Green bar: the gain of chromosome. Yellow
frame: Recurrently Altered Regions (RARs).
doi: 10.1371/journal.pone.0083465.g002
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AKR1B10 mRNA levels than the HBV(-)/AFB1(-) group (1.11
vs. 0.76, P = 0.01). AKR1B10 protein was expressed at
significantly higher levels in the HBV(+)/AFB1(+) group
compared to the other three groups (2.84 vs. 1.70, 2.45, and
1.53 P ≤ 0.041). Samples from the HBV(-)/AFB1(+) group
Table 3. Univariate and multivariate analysis of patient
characteristics and RARs with tumor-free survival using
COX regression models.
Variables Univariable  Multivariable
 OR (95% CI) P-value  OR (95% CI) P-value
Age (year) 1.00 (0.96, 1.04) 0.869    
Gender 1.84 (0.25, 13.75) 0.552    
Tumor size (>3cm) 1.30 (1.12, 1.50) <0.001*    
AFP > 400 ng/ml 4.08 (1.35, 12.32) 0.013*  7.87 (2.25,27.57) 0.001
*
HBV 1.00 (0.43, 2.31) 0.994    
AFB1 1.80 (0.78, 4.15) 0.169    
Liver cirrhosis 32.24 (0.45, 2,307.29) 0.111    
BCLC grade      
A Reference     
B 8.30 (2.17, 31.82) 0.002*    
C 7.90 (2.49, 25.04) <0.001*    
Edmondson grade 2.22 (0.94, 5.25) 0.071    
TNM stage 6.65 (2.50, 17.73) <0.001*  6.70 (2.00,22.42) 0.002
*
Invasion and
metastasis 7.62 (2.64, 21.99) <0.001
*    
1p31.2-p36.2 0.73 (0.32, 1.64) 0.444    
1q21.1-q44 0.94 (0.41, 2.15) 0.875    
2q23.2-q37.2 0.86 (0.35, 2.08) 0.736    
4q13.3-q35.2 0.60 (0.25, 1.42) 0.242    
5p13.2-p15.3 0.92 (0.38, 2.22) 0.857    
6p12.1-p25.2 0.99 (0.43, 2.29) 0.976    
6q14.1-q26 0.89 (0.36, 2.17) 0.791    
7q11.2-q35 0.83 (0.36, 1.92) 0.662    
8p12-p23.2 3.71 (1.40, 9.81) 0.008*  3.29 (1.03,10.52) 0.045
*
8q11.2-q24.3 1.03 (0.44, 2.41) 0.954    
9p21.1-p24.2 0.58 (0.24, 1.41) 0.232    
10q21.3-q26.2 1.02 (0.45, 2.34) 0.962    
13q12.1-q21.2 1.75 (0.77, 4.00) 0.184    
14q21.3-q32.2 0.81 (0.34, 1.94) 0.631    
16p12.1-p13.2 1.04 (0.45, 2.38) 0.928    
16q12.1-q24.1 0.83 (0.36, 1.89) 0.652    
17p12-p13.3 1.23 (0.45, 3.33) 0.690    
17q12-q25,2 1.54 (0.64, 3.67) 0.333    
18q12.3-q22.3 2.30 (0.94, 5.61) 0.069    
19p13.1-p13.3 2.86 (1.14, 7.15) 0.025*    
19q13.2-q13.4 0.85 (0.35, 2.07) 0.718    
21q21.3-q22.2 1.35 (0.59, 3.09) 0.483    
22q11.2-q13.2 1.19 (0.51, 2.81) 0.689    
X 0.98 (0.41, 2.34) 0.969    
Y 1.02 (0.45, 2.30) 0.971    
* Indicates a significant association with tumor-free survival
doi: 10.1371/journal.pone.0083465.t003
showed significantly higher AKR1B10 protein levels than the
HBV(-)/AFB1(-) group (2.45 vs. 1.53, P < 0.001) and the
HBV(+)/AFB1(-) group (2.45 vs. 1.70, P < 0.001) (Figure 4B ,
4D).,
Discussion
A variety of risk factors have been associated with HCC.
HBV infection and AFB1 exposure contribute to HCC
development in more than 80% of the HCC cases in the
Guangxi area of Southern China [4]. Given that development of
HCC is a complex process associated with the accumulation of
genetic changes, we examined whether patients exposed to
HBV or AFB1 had specific molecular changes that may give
insight to HCC tumorigenesis.
We found that chromosomal instability was not equally
distributed across all the chromosomes in all patients. We
found a total of 573 chromosomal abnormalities in our study
patients. Of these, 184 resulted in increased and 389 in
decreased genetic material with a mean gain or loss of 5.7 and
12.2 per patient, respectively. Twenty-five RARs were identified
with a high incidence (≥50% of tumors) of chromosomal
alterations at RARs: 8q11.2-q24.3, 17p12-p13.3, 19p13.1-
p13.3. Loss of 8p12-p23.2 and loss of 19p13.1-p13.3 were
associated with high TNM III stage tumors (92.9% and 92.9%,
respectively). A total of 133 differentially expressed proteins
were identified, 72 of which were commonly up-regulated or
down-regulated in all of the 4 subgroups, and 24 of which were
commonly changed in HBV(+)/AFB1(+), HBV(+)/AFB1(-), and
HBV(-)/AFB1(+) groups. Of the 133 differentially expressed
proteins, 51.8% mapped within identified RARs. The most
common biological processes affected by HBV and AFB1
status were detoxification and drug metabolism pathways,
antigen processing, glycolysis, and anti-apoptosis pathways.
Analysis of AKR1B10 expression indicated that changes in its
mRNA and protein expression were influenced by AFB1
exposure. These data identify a number genetic and gene
expression alterations associated with HBV- and AFB1- related
HCC and may give insight into HCC tumorigenesis. A strength
of this study was the availability of a unique population of HCC
patients who were exposed to both hepatitis viruses and AFB1
[7].
Previous studies have investigated the genetic abnormalities
of HCC including screening for chromosomal regions with
frequent allelic imbalance, comparative genomic hybridization,
analysis of differential gene and protein expression, and
changes in microRNA profiles [15–20,23,24]. Pathways that
have been implicated in HCC tumorigenesis include P53/ARF,
RB/INK4A, and WNT/ß-catenin pathways. Other genetic
changes include chromosomal alterations and abnormal
methylation of the promoters of tumor suppressor genes and
repetitive sequences [16–18,20,23,24]. The methylation of
repetitive sequences may influence chromosomal stability, and
activate retrotransposons and microRNA expression.
Chromosomal alterations are a major factor leading to the
development of HCC. By utilizing array-based comparative
genomic hybridization (aCGH) technology with the capacity to
screen for DNA copy changes across the entire genome at
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high resolution, we identified a large number of chromosomal
abnormalities in HCC cases from the Guangxi area. Of the
chromosomal alterations detected, we showed that 21 of the
25, including the 10 most frequent RARs (1p31.2-p36.2,
1q21.1-q44, 4q13.3-q35.2, 7q11.2-q35, 8p12-p23.2, 8q11.2-
q24.3, 13q12.1-q21.2, 16p12.1-p13.2, 16q12.1-q24.1, 17p12-
p13.3) were consistent with those reported in previous studies
[16–18,20]. Not all of the previous studies investigated the
association of these abnormalities with HBV or AFB1 exposure,
suggesting that the commonality between ours and these
previous studies reflect aspects of HCC tumorigenesis that are
independent of HBV or AFB1 exposure.
Three RARs (2q23.2-q37.2; 18q12.3-q22.3; 19p13.1-p13.3)
identified in this study have rarely been reported in previous
studies. It is important to note that loss of 19p13.1-p13.3 was
present in > 50% of the cases, suggesting it is unlikely to be a
false positive, and that it may be a genetic characteristic of
HCC from Guangxi area. These 3 RARs were similar across
the 4 patient subgroups, suggesting that HBV and AFB1 likely
do not have a strong affect in inducing these chromosomal
abnormalities, and that there may be other environmental or
genetic factor(s) present within the Guangxi area that is driving
these chromosomal instabilities. At this time, it is not clear if
these instabilities directly influence HCC development or are a
consequence of the disease. The idea that 8p12-p23.2 could
be a consequence of the disease arises from the finding that
the frequency of 8p12-p23.2 loss was significantly associated
with late stage tumors and was an independent factor
associated with tumor-free survival. This idea is also supported
Figure 3.  Venn diagram depicting the overlap of differentially expressed proteins quantified in the 4 groups based on HBV
and AFB1 status.  The number in parentheses indicates the number of differentially expressed quantified proteins in each group.
doi: 10.1371/journal.pone.0083465.g003
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by a previous study that found deletion of chromosome 8p was
associated with HCC metastasis [25].
Although not statistically significant, we found that loss of
4q13.3-q35.2, 13q12.1-q21.2, as well as gain of 7q11.2-q35
was observed with a higher frequency in the HBV(+)/AFB1(+),
HBV(+)/AFB1(-) and HBV(-)/AFB1(+) groups compared to the
HBV(-)/AFB(-) group, suggesting that genes covered by these
3 RARs may play a role in HBV- and/or AFB1-related HCC
carcinogenesis. The lack of statistical significance could be due
to the small sample size or due to the fact that HBV or AFB1
trigger chromosome instability randomly, and do not induce
specific chromosomal gain or loss. However, our findings were
consistent with a study that investigated HCC patients from the
Shanghai area where there was high exposure to HBV and
AFB1 that found a higher frequency of loss of 4q and 13q in
tumors in HCC patients compared with Hong Kong, Japan, and
the United States [26]. Several other studies have
demonstrated that HBV-related chromosomal rearrangements
map to 4q [27–29]. Loss of 4q and 13q was also reported to
correlate with the etiology of HBV-related HCC tumorigenesis
[30]. Based on our data and these studies, we suggest that
despite our small sample size, our findings indicated that the
genetic alterations were in fact associated with HBV and AFB1-
related HCC. To our knowledge, our study is the first report of
gain in 7q (7q11.2-q35) in AFB1-related HCC patients. We
recognize that it will be important to validate our data using
larger sample sizes.
We identified 133 proteins whose expression levels were
significantly different between normal liver and HCC tissues.
Sixty nine (51.8%) of these proteins mapped within RARs
which implied that the genomic DNA copy number alterations,
amplification and loss, could partially contribute to the
dysregulation of these proteins. Of the 133 differentially
expressed proteins, 16 proteins (GSTA1, CYP2A13, ADH4,
ADH1C, HADH, CYP2E1, CYP27A1，ADH1A, ADH6, EPHX2,
EPHX1, AKR7A2, AKR1C1, AKR1C4, AKR1B10, and AOX1)
involved in detoxification and drug metabolism pathway, were
identified in five families (GSTs, ADH, CYPs, EPHX and
AKRs). Several of these proteins map to or close to RARs. For
example, alcohol dehydrogenase 4 (ADH4), alcohol
dehydrogenase 1C (ADH1C), Alcohol dehydrogenase 1A
(ADH1A), and alcohol dehydrogenase 6 (ADH6) are on 4q13.3-
q35.2, epoxide hydrolase 2 (EPHX2) is on 8p12-p23.2l, and
Aldo-keto reductase family 1 member B10( AKR1B10) is on
7q11.2-q35. Previous studies showed that GST, ADH and CYP
family members were altered by HBV infections [7,31].
Similarly in this study, we found that the expression of these
family members was down-regulated in the HBV(+)/AFB1(+)
group and about half of the family members were down
regulated in the HBV(+)/AFB1(-) or in the HBV(-)/AFB1(+)
group, suggesting both HBV and AFB1 exposure influence
expression. Since AFB1 requires detoxification, dysfunction of
AFB1 by the phase I and phase II pathways have been
implicated in HCC development [32]. These findings suggest
that HBV infection might compromise the ability of hepatocytes
to detoxify chemical carcinogens by down-regulating the
detoxification-related proteins making HBV-infected liver cells
more susceptible to carcinogens such as AFB1. This may
reflect a synergy between HBV and AFB1.
Up-regulation of HSPs has been reported in several cancers
(e.g., breast, renal and bladder cancers, various leukemias, as
well as HCC.) [33–36] and plays a role in controlling apoptosis
and cellular immunity [37–41]. These findings are consistent
with our results that found 9 stress-associated proteins
(HSP90AA1, HSP90AB1, GRP78, HSPA1A, GRP75, HSPA8,
HSPD1, HSPE1 and HSPB1) which were up-regulated in HCC
Table 4. Biological process categories of differentially expressed proteins.
Category P-Value# Term (No.) Gene Name▲
Detoxification and drug metabolism
pathway 1.22E-6 GO:000098(2)
GSTA1, CYP2A13, ADH4, ADH1C, CYP2E1, ADH1A, ADH6, EPHX2, EPHX1, AKR1C1,
AKR1C4, AKR1B10, AKR7A2，AOX1, HADH, CYP27A1.
Antigen processing and presentation
pathway 0.002541 GO:000645(7)
HSP90AB1, HSP90AA1, PDIA3, HSPA1A, HSPA5, CALR, CANX, HSPA8, GPP78, GRP75,
HSPD1, VCP,
Glycolysis pathway 6.32E-7 GO:000609(6) LDHA, PKM2, ALDOB, PGM1, PGK1, MDH2, ENO1
Anti-apoptosis pathway 5.68E-4 GO:000691(6) HSP90AB1, HSP90AA1, APOE, CFL1, TGM2, HSPB1, HSPA1A, GRP75, HSPD1, SOD1,RPS27A, GRP78, HSPE1
Fatty acid metabolic process pathway 0.010114 GO:000663(1) ACAA2, CRYL1, ACSL1, EPHX2, HADH, SLC27A5
Response to unfolded protein 4.29E-7 GO:000698(6) HSP90AB1, HSP90AA1, VCP, HSPB1, HSPE1, HSPA1A, HSPD1, HSPA8
Macromolecular complex assembly 1.51E-6 GO:006500(3) HSP90AA1, OTC, ALDOB, SLC9A3R1, CALR, FLNA, HIST1H4A, FGA, VCP, FGB, APOE,HIST1H2BJ, TGM2, TOMM22, GNMT, HSPD1, TUBA1B, AKR1C1, HIST1H2AA,
Steroid metabolic process 3.91E-4 GO:000820(2) ACAA2, AKR1C4, CYP27A1, APOE, AKR1B10, COMT, AKR1C1, SLC27A5
Coenzyme metabolic process 7.03E-5 GO:000673(2) MTHFD1, GSTA1, ALDH1L1, ALDOB, FTCD, SOD1, DCXR, MDH2
Homeostasis in body 0.020564 GO:004887(8) PYGL, APOE, OTC, TXN, EPHX2, TGM2, PDIA6, PDIA4, SOD1, SLC9A3R1, CALR, AKR1C1
Response to nutrient levels 0.010081 GO:003166(7) ACSL1, ALDOB, CTSD, HSPA5, COL1A1, SOD1
Circulatory system process 0.035458 GO:000301(3) APOE, EPHX2, ABAT, SOD1, HBB
Cytoskeleton organization 0.026019 GO:000701(0 APOE, CALD1, CFL1, SOD1, CALR, TUBA1B, FLNA, MYH10
# Significance level of enrichment was calculated using hypergeometric distribution and P<0.05 was considered significant.
▲ Gene symbols for the differentially expressed proteins
doi: 10.1371/journal.pone.0083465.t004
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Figure 4.  The AKR1B10 gene location and its expression levels validated by Reverse Transcriptase PCR and Western
Blot.  (A) AKR1B10 is located on RAR: 7q11.2-q35 (position 7q33.1) a chromosomal region that showed a high instance of
instability in HBV(+)/AFB1(+) ,HBV(+)/AFB1(-) and HBV(-)/AFB1(+) groups. (B) Representative RT- PCR and Western blot images
of AKR1B10 in the 4 groups. T1–T4 ,T5-T8, T9-T12 and T13-T16 were HCC samples obtained from HBV(+)/AFB1(+) , HBV(+)/
AFB1(-), HBV(-)/AFB1(+) and HBV(-)/AFB1(-) groups, respectively. Human GAPDH was used as an internal control. (C) The
regression analysis showed a significant correlation between AKR1B10 expression level (both mRNA level and protein level) and
AKR1B10 copy number. (D) RT-PCR and Western blot analysis of AKR1B10 expression. Mean mRNA and protein expression
levels of AKR1B10 were calculated by RT-PCR and Western blotting for the 4 subgroups. Human GAPDH was used as an internal
control. * indicated a significant difference (P<0.05) as compared to HBV(+)/AFB1(+), †indicated a significant difference (P<0.05) as
compared to HBV(+)/AFB1(-), ‡ indicated a significant difference (P<0.05) as compared to HBV(-)/AFB1(+).
doi: 10.1371/journal.pone.0083465.g004
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tumors and were involved in the anti-apoptosis and antigen
processing and presentation pathways. Over-expression of
members of HSP 70, HSP 90 and GRPs gene families in
human HBV-associated HCC has been previously described
[42] and HSP 90 has been identified as an essential host factor
for HBV replication [43]. These findings suggested HSPs may
be important for HBV-related HCC. We showed that 9 stress-
associated proteins (HSP90AA1, HSP90AB1 GRP78 HSPA1A
GRP75 HSPA8 HSPD1, HSPE1 and HSPB1) were up-
regulated in HBV(+)/AFB1(+), HBV(+)/AFB1(-) and HBV(-)/
AFB1(+) groups, suggesting these proteins not only play a role
in HBV-related HCC but also in AFB1-related HCC. These
factors are primarily involved in anti-apoptotic pathways and
antigen-presenting regulation of cell-mediated immunity, and it
is possible that changes in the activity of these molecular
pathways is result in HCC.
AKR1B10 is highly expressed in solid tumors of several
tissues including lung, liver, and pancreas, and thus has
received considerable interest as a relevant biomarker for the
development of those tumors [44–47]. In addition, increased
AKR1B10 expression is associated with smoking in patients
with lung cancer and has been proposed to be a potential
biomarker for smoking-induced lung cancer [44,46,47].
Currently, it is not clear how AKR1B10 promotes
tumorigenesis. It is possible that it may regulate cell
proliferation in non-small cell lung cancer as increased
AKR1B10 expression is correlated with changes in genes
involved in the cell cycles such Ki-67, cyclin E, GalNAcT3, and
GnT-V [44,48]. Alternatively, AKR1B10 may promote lung
cancer via its enzymatic activity that inhibits the conversion of
ß-carotene to retinoic acid and promotes the conversion of
highly reactive aldehyde and ketone groups into hydroxyl
groups in neoplastic cells resulting in an inhibition of apoptosis
[44,49]. In this study, expression of a relatively large number of
proteins was altered in the HCC tumors studied. However, we
focused on AKR1B10 and evaluated if changes in its
expression were associated with HBV or AFB1 exposure for a
number of reasons: 1) Our proteomic data suggested that
AKR1B10 was expressed at significantly higher levels in
patients who were HBV (+) / AFB1 (+) and HBV (-) / AFB1 (+)
(9.22 and 5.15, respectively) compared to patients who were
HBV (+) / AFB1 (-) or HBV (-) / AFB1 (-) (2.00 and 1.10,
respectively); 2) The gene encoding AKR1B10 is located on
chromosome 7q33.1, within the high genetic variation region
(7q21.1-q35), and regression analysis showed a significant
correlation between AKR1B10 expression level and change in
its copy number; 3) The tobacco-specific chemical carcinogen
NNK, has been shown to be a substrate of AKR1B10 and
AKR1B10 is upregulated in smoking-related non-small cell lung
cancer. Since AFB1 is a typical chemical carcinogen, we
hypothesized that the high expression of AKR1B10 was likely
associated with high exposure to AFB1. Moreover, our
preliminary data showed that overexpression of AKR1B10
played a role in AFB1-mediated carcinogenesis.
In our study, the expression level of AKR1B10 was higher in
the HBV(+)/AFB1(+) and HBV(-)/AFB1(+) groups compared to
the HBV(+)/AFB1(-) and HBV(-)/AFB1(-) groups suggesting
that AKR1B10 might be involved in AFB1 carcinogen-related
hepatocarcinogenesis. Currently, it is not clear if AFB1 has a
direct effect by perhaps altering DNA associated with
regulatory regions of the AKR1B10 gene, or acts indirectly via
one or more molecular pathways to alter AKR1B10 expression.
Additional experiments are necessary to investigate this
question.
The major limitation of this study is the small sample size,
particularly for the array-based comparative genomic
hybridization and isobaric tagging reagent quantitative analysis.
It is essential to perform larger studies using samples which
have or have not been exposed to HBV or AFB1, in order to
further explore the processes involved in HCC. As our analysis
relied on tumor tissue, it is not clear which factor or
chromosomal aberrations directly influence tumorigenesis or
are a result of the cancer. Moreover, this analysis does not
elucidate the primary cause of the disease.
Conclusions
We identified 25 RARs and 133 differentially expressed
proteins in HCC tumors from patients in Guangxi, China. Our
analysis indicated that loss of 8p12-p23.2 was an independent
factor associated with tumor-free survival, loss of 19p13.1-
p13.3 may be a genetic characteristic of HCC from Guangxi
area, and genetic abnormalities in 4q13.3-q35.2, 13q12.1-
q21.2 and 7q11.2-q35 may play a role in both HBV- and AFB1-
related HCC carcinogenesis. Our findings also suggest that 1)
upregulation of heat-shock proteins and down regulation of
metabolic enzymes and detoxification proteins may be
common in HBV- and AFB1-related HCC carcinogenesis, and
2) over-expression of AKR1B10 may be involved in AFB1-
related HCC carcinogenesis. Taken together, our study
provides additional insights into the genetic mechanisms of
HBV- and AFB1-related HCC development and demonstrates
the complexity of the disease.
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